Hospital Duran i Reynals

L'Hospitalet de Llobregat, Barcelona 08908

0 studies enrolling now · 6 studies all time

What they study most

Advanced Cancer, Biliary Tract Cancer, Chronic Lymphocytic Leukemia, Clear-cell Metastatic Renal Cell Carcinoma, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Ovarian Cancer, Low-grade Serous Peritoneal Cancer, Lymphoma, Mantle-Cell, Metastatic Cancer, Small Lymphocytic Lymphoma

Studies at this site

• A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) — Running, not enrolling
• Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) — Running, not enrolling
• Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) — Running, not enrolling
• A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer — Stopped early
• MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma — Completed